October 15, 2020

MAR Stock
Ticker Update

Replimune Group Inc [REPL] Targets $50 Ahead of SITC Meeting

Biotechnology Company Replimune Inc [NASDAQ: REPL] announced yesterday that it will be presenting data from its lead product candidate RP1, together with its first single-agent safety and the RP2 in advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting. The meeting

Equity Analysis

Novan (NOVN) Rises By 30% After Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2

The strong preclinical results of Novan’s antiviral effect of nitric oxide-based medicine against SARS-CoV-2 puts the company in a place to develop an intranasal formulation of berdazimer sodium for use in coronavirus program. Shares of Novan Inc. (NOVN) has skyrocketed after the company today announced positive in vitro outcomes reflecting the potential efficacy of its NITRICIL™ platform technology as